Wishing ev_老虎社区_美港股上老虎

KongSH
2021-10-12

Wishing everyone another day of gain in investment… Huat Ah!!! 😄😄

After-Hours Stock Movers:Quanterix, Relay Therapeutics, Matson and more

After-Hours Stock Movers: Quanterix Corp 20.4% HIGHER; announced today that its Simoa® phospho-Tau 1

After-Hours Stock Movers:Quanterix, Relay Therapeutics, Matson and more

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":826878293,"tweetId":"826878293","gmtCreate":1634007451825,"gmtModify":1634007451960,"author":{"id":4091169623174150,"idStr":"4091169623174150","authorId":4091169623174150,"authorIdStr":"4091169623174150","name":"KongSH","avatar":"https://static.tigerbbs.com/4db5a338d9f077992726659f508a7685","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wishing everyone another day of gain in investment… Huat Ah!!! 😄😄</p></body></html>","htmlText":"<html><head></head><body><p>Wishing everyone another day of gain in investment… Huat Ah!!! 😄😄</p></body></html>","text":"Wishing everyone another day of gain in investment… Huat Ah!!! 😄😄","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/826878293","repostId":2174186522,"repostType":4,"repost":{"id":"2174186522","kind":"news","pubTimestamp":1633995600,"share":"https://www.laohu8.com/m/news/2174186522?lang=&edition=full","pubTime":"2021-10-12 07:40","market":"us","language":"en","title":"After-Hours Stock Movers:Quanterix, Relay Therapeutics, Matson and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2174186522","media":"StreetInsider","summary":"After-Hours Stock Movers:\nQuanterix Corp 20.4% HIGHER; announced today that its Simoa® phospho-Tau 1","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/QTRX\">Quanterix Corp</a> 20.4% HIGHER; announced today that its Simoa® phospho-Tau 181 (pTau-181) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need. The program is designed to enable accelerated development, assessment and review processes, with the intention to provide patients with more timely access to breakthrough technologies or devices.</p>\n<p><a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> 8.9% LOWER; commenced an underwritten public offering of $350 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Relay Therapeutics.</p>\n<p><a href=\"https://laohu8.com/S/MATX\">Matson</a> 5.1% HIGHER; announces preliminary third quarter financial results, provides a business update and announces that its third quarter earnings call will be held on November 3, 2021.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers:Quanterix, Relay Therapeutics, Matson and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers:Quanterix, Relay Therapeutics, Matson and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19046085><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nQuanterix Corp 20.4% HIGHER; announced today that its Simoa® phospho-Tau 181 (pTau-181) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19046085\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLAY":"Relay Therapeutics","MATX":"Matson Inc","QTRX":"Quanterix Corp"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19046085","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2174186522","content_text":"After-Hours Stock Movers:\nQuanterix Corp 20.4% HIGHER; announced today that its Simoa® phospho-Tau 181 (pTau-181) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need. The program is designed to enable accelerated development, assessment and review processes, with the intention to provide patients with more timely access to breakthrough technologies or devices.\nRelay Therapeutics 8.9% LOWER; commenced an underwritten public offering of $350 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Relay Therapeutics.\nMatson 5.1% HIGHER; announces preliminary third quarter financial results, provides a business update and announces that its third quarter earnings call will be held on November 3, 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":804,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":57,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}